SHL Medical | January 24, 2024
SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging services in the United States, this collaboration extends high-quality CMO options to Europe.
Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward."
Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base.
John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision."
About SHL Medical
As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems.
In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem.
Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth.
About SteriPack Group
SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors.
SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.
Rudolf Riester GmbH | January 29, 2024
Rudolf Riester GmbH, a global leader in medical technology, proudly announces the full market launch of its comprehensive Telemedicine offering. Already in active use across Europe, the Middle East, and Africa, the solution from the trusted Riester brand delivers industry-leading quality and versatility through integration of a broad range of medical devices to meet the needs of diverse user scenarios.
"Since its founding 75 years ago, Riester has been a pioneer in providing accurate and efficient diagnostic devices for front-line healthcare. We have brought this passion and expertise to the creation of our telemedicine solution," said Dr. Georgiana Gasquères, Global Business Unit Director, Telemedicine at Riester. "Now we empower healthcare providers worldwide with the tools they need to deliver accurate diagnosis and exceptional care to every patient, everywhere, and to do it more sustainably." Riester is demonstrating its Telemedicine Case and Cart offerings at the Arab Health show in Dubai, 29 January – 1 February 2024, at booth SA.E30.
Traveling nurses with South African healthcare innovator EQiGate are already evaluating dozens of patients every week with the Riester Telemedicine Case. "EQiGate selected the Riester Telemedicine solution for its high quality, comprehensiveness, and versatile, Windows-based compatibility with our portfolio of operating applications," stated Braam Kruger, CEO at EQiGate. "The Riester solution integrates seamlessly with our Hospital at Home concept, enabling us to bring the hospital to the patient, a healthcare paradigm shift that yields significant cost and time savings for both the healthcare system and the patient."
At Arab Health, Riester is showcasing the integration of their industry-leading ri-sonic® E-stethoscope with the eMurmur® AI platform. Digital auscultation with ri-sonic and eMurmur AI enables the early detection and analysis of heart murmurs, informing better, more timely decisions about treatment pathways.
To demonstrate their commitment to raising heart health awareness and improving quality of life through accurate and efficient diagnosis, Riester is offering complimentary advisory heart checks to all exhibition attendees at their booth at Arab Health, conducted by a professional cardiologist. "Our participation at Arab Health reaches beyond showcasing our technological advancements; it is about educating and engaging with the public – including Arab Health attendees – and healthcare professionals," said Irina Zhdanova, CEO of Riester. "By providing free advisory heart checks, we emphasise the significance of regular cardiac health assessments and demonstrate how innovative technology can be a pivotal tool in advancing diagnostic cardiac care to improve health outcomes. This is a perfect way to honor Riester’s 75-year heritage and act on our vision and mission."
About Rudolf Riester GmbH
Since its founding in Germany in 1948, Rudolf Riester GmbH has been a pioneering force in improving quality of life through accurate and efficient diagnosis on the front-line of healthcare. By developing and manufacturing high-quality, market-leading medical diagnostic products, Riester has earned a global reputation for quality, reliability, and innovation in the healthcare sector, with a presence in over 150 countries. Specializing in diagnostic devices, Riester's product portfolio includes telemedicine solutions as well as stethoscopes, blood pressure monitors, otoscopes, ophthalmoscopes, and other medical equipment. Riester is part of the Halma plc group of companies.
Medtronic | January 08, 2024
Medtronic plc a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.
The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024. Medtronic will begin the phased commercial launch in Europe in the summer of 2024. Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor.
The MiniMed™ 780G system is Medtronic's most advanced insulin delivery system, automatically adjusting and correcting† glucose levels every 5 minutes.§ It's the world's only system with a Meal Detection™ feature‡ that is designed to reduce post-meal hyperglycemia when users occasionally forget to give themselves insulin or underestimate the number of carbs in their snacks or meal. The system, which is available with the world's only 7-day infusion set, also features one of the lowest glucose target settings (as low as 100 mg/dL) of any automated insulin delivery system. With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes. With both Simplera Sync™ sensor and the Guardian™ 4 sensor, no fingersticks are required.
"A challenging aspect of living with diabetes is counting carbohydrates and dosing the right amount of insulin before consuming snacks and meals. Many people underestimate their carbs, which can lead to high blood sugars (hyperglycemia). Prolonged hyperglycemia can lead to serious health problems impacting the eyes, major organs, and even cognitive function, which is particularly concerning in developing children," Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences "With its responsive algorithm, the MiniMed™ 780G system can help people living with diabetes even when they occasionally forget to bolus or undercount their carbs. The system takes on more of the work involved in diabetes management and helps alleviate mental burden."
"We're incredibly proud that the MiniMed™ 780G system continues to be the most widely used automated insulin delivery system in Europe since we launched it in 2020. Real-world data on over 100,000 users on the system across many geographies and cultures shows that when using recommended settings the system is delivering an average Time in Range of nearly 80%, raising the bar on what 'good' looks like2," said Que Dallara, EVP and President, Medtronic Diabetes. "With the introduction of Simplera Sync™ sensor, we're able to offer the proven benefits of our MiniMed™ 780G system with our newest and most comfortable sensor that can be applied in under 10 seconds."
The MiniMed™ 780G system with Simplera Sync™ sensor is indicated for ages 7+ and compatible with iOS and Android. Simplera Sync™ sensor is not approved by the FDA and is limited to investigational use in the U.S.
Simplera Sync™ sensor is designed to leverage Medtronic's advanced AID algorithm as part of its MiniMed™ 780G system while having a similar look and feel as the Simplera™ CGM. The Simplera™ CGM for integrated use with the InPen™ smart insulin pen received CE Mark in September 2023.
About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
Aya Healthcare | January 17, 2024
Aya Healthcare, the largest healthcare talent software and staffing company in the United States, today announced the acquisition of ID Medical, a leading workforce solutions provider in the United Kingdom (U.K.). ID Medical brings over 20 years of experience providing the National Health Service (NHS) and other healthcare organizations with innovative workforce solutions, including workforce management, international recruitment and temporary healthcare staffing.
As part of the acquisition, ID Medical will make Aya Healthcare’s market-leading technology available to the NHS and U.K.-based clinicians. The companies plan to share best practices from each market with their respective clients.
“We are excited about ID Medical joining the Aya family of brands. We believe that we will deliver enhanced value to our respective clients and clinicians through this cross-Atlantic collaboration,” said Alan Braynin, president and CEO of Aya Healthcare.
ID Medical will continue to operate as its own brand in the U.K., supporting thousands of healthcare professionals and hundreds of healthcare organizations.
“We are excited to join Aya in our shared mission to transform the healthcare industry worldwide,” said Deenu Patel, CEO of ID Medical. “With Aya’s support, we’ll have access to additional resources, technology and expertise to enhance our services and expand our impact.”
About Aya Healthcare
Aya Healthcare is the largest healthcare talent software and staffing company in the United States. Aya operates the world’s largest digital staffing platform delivering every component of healthcare-focused labor services, including travel nursing and allied health, per diem, permanent staff hiring, interim leadership, locum tenens and non-clinical professionals. Aya’s software suite, which includes vendor management, float pool technology, provider services and predictive analytics, provides hospital systems greater efficiencies, superior operating results and reduced labor costs. While technology drives efficiency and scale, Aya’s 7,000+ global employees power the company to deliver unparalleled accountability and exceptional experiences for clients and clinicians. Aya’s company culture is rooted in giving back and supports organizations around food security, education, healthcare, safe shelter and equity.